Get Cash Back and $0 Commissions
+ The Power of TradeStation
PRNewswire 8-Oct-2018 8:00 AM
PR Newswire
DUBLIN, Oct. 8, 2018
DUBLIN, Oct. 8, 2018 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company, today announced it will present data from its gastroenterology portfolio at the American College of Gastroenterology Annual Scientific Meeting (ACG), from October 5-10, 2018 in Philadelphia, PA.
"Allergan is working to change treatment paradigms across gastroenterology with our Open Science research and development model," said David Nicholson, Chief Research and Development Officer, Allergan. "We are committed to uncovering the full potential of our approved medicines as well as collaborating with leading researchers to advance the investigational therapies in our pipeline. We look forward to showcasing our latest research to gastroenterologists at this important annual meeting."
Allergan will present efficacy and safety data from RELIEF, a Phase 4, multicenter, multinational, randomized, placebo-controlled, double-blind study of VIBERZI® (eluxadoline) CIV in patients with irritable bowel syndrome with diarrhea (IBS-D) who report inadequate symptom control with loperamide (poster #0344).
Allergan will also present data on two investigational drugs, which include:
About VIBERZI® (eluxadoline)
Eluxadoline is marketed by Allergan in the United States as VIBERZI®. VIBERZI® is a twice daily, oral medication used to treat adults with irritable bowel syndrome with diarrhea (IBS-D). VIBERZI® has mixed opioid receptor modulator activity; it is a mu- and kappa-opioid receptor agonist and a delta-opioid receptor antagonist. VIBERZI® is thought to decrease visceral hypersensitivity and control GI motility, based on nonclinical studies. VIBERZI® is indicated for the treatment of IBS-D in adult men and women. Please also see full Prescribing Information.
IMPORTANT SAFETY INFORMATION
Contraindications
VIBERZI is contraindicated in patients:
Warnings and Precautions
Pancreatitis:
Sphincter of Oddi Spasm:
Hypersensitivity Reactions:
Constipation:
Adverse Reactions
The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.
About Allergan plc
Allergan plc (NYSE:AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; uncertainty associated with financial projections, debt reduction, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
CONTACTS: Allergan
Investors:
Daphne Karydas
(862) 261-8006
Karina Calzadilla
(862) 261-7328
Media:
Amy Rose
(862) 289-3072
Sara Bosco
(862) 261-8130
View original content to download multimedia:http://www.prnewswire.com/news-releases/allergan-presents-new-research-at-the-american-college-of-gastroenterology-annual-scientific-meeting-acg-2018-300725562.html
SOURCE Allergan plc